Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Deepali L. Kundnani has a total of 197 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Tumor γδ T-cell abundance is associated with favorable cancer treatment outcomes

    by Xingzhi Niu, Deepali Kundnani, Mikaela Dicome, Luis Tafoya, Li Song, Murad Mamedov, X. Shirley Liu, Avinash D. Sahu

    Purpose: Clinical response to immune checkpoint blockade (ICB) remains variable. We performed a reference-wide screen to identify immune-cell populations in the tumor microenvironment (TME) associated with benefit across treatment modalities and tumor types. Experimental Design: We analyzed pretreatment bulk tumor RNA-seq to identify RNA-abundance patterns associated with favorable outcomes in (1) published ICB cohorts with response labels and (2) pretreatment TCGA cohorts with survival outcomes. To identify associated cell types, we compared favorable expression patterns to previously determined patterns for 157 cell types defined by the Human Primary Cell Atlas (HPCA), spanning immune, stromal, vascular, and epithelial lineages. Cell types were associated with favorable outcomes using Cox models (TCGA survival) and mixed-effects models of responder status that accounted for cohort, therapy class, tumor type (ICB cohorts). ICB analyses were restricted to pretreatment samples. Random-effects meta-analysis was used for the PRECOG cross-platform replication. After γδ T-cells emerged as the top-ranked population associated with ICB response, we adjusted γδ associations for CD8 + T-cell abundance, and evaluated γδ signals with TRUST4-based T-cell receptor gamma (TRG) and delta (TRD) gene reconstruction and single-cell RNA-seq. To test whether ICB-favorable cellular landscapes were shared with non-immunotherapy treatment response, we used TCGA RECIST-evaluable treatment records to derive immune-cell profiles associated with treatment response for chemotherapy, radiation, targeted therapy, and hormone therapy. Results: The γδ T-cell program was the top-ranked cell-type program associated with ICB response and was also among the programs most strongly associated with favorable TCGA survival. Cell types associated with ICB response showed strong descriptive concordance with the chemotherapy-response profile derived from recorded TCGA outcomes (Pearson r of ranks = 0.92) and moderate concordance with the analogous radiation-associated profile (r = 0.58). Analyses of targeted and hormone therapies were limited by small sample sizes and showed weaker concordance. In pretreatment tumor biopsies, inferred γδ T-cell abundance was associated with ICB response and with survival, and these associations were not explained simply by CD8 + T-cell abundance. In TCGA, TRUST4-derived γδ T-cell receptor (TCR) abundance estimates correlated with signature-based γδ scores and stratified survival. In independent single-cell RNA-seq datasets, higher γδ TCR RNA abundance was also associated with a higher rate of ICB response. Conclusion: A reference-wide cell-type screen identified γδ T-cells as the leading population associated with ICB response, and pretreatment γδ T-cell abundance was also associated with favorable outcomes in immunotherapy and non-immunotherapy settings. The evidence is associative and varies in strength by tumor context but supports prospective evaluation of γδ T-cell abundance as a component of pretreatment immune profiling alongside CD8, B-cell/TLS, stromal, and epithelial-state features. Translational Relevance: Across cancers, clinical response to immune checkpoint blockade (ICB) is variable, with inconsistent performance from established biomarkers such as PD-L1 and tumor mutation burden. We asked which immune-cell transcriptional programs were associated with favorable outcomes across immunotherapy and non-immunotherapy treatment settings. Using pretreatment bulk tumor RNA-seq from published ICB cohorts and TCGA, we evaluated the inferred abundance of 157 subtypes in the tumor microenvironment (TME) with a common gene-level and sample-level framework. Pretreatment TMEs enriched in lymphoid cells or γδ T-cells were associated with ICB response and with favorable survival. The immune-cell landscape associated with favorable ICB outcomes was strongly concordant with chemotherapy response and moderately concordant with radiation response. The association between γδ abundance and favorable outcomes remained after accounting for CD8 + T-cell abundance. These observational findings support γδ T-cell abundance as a candidate for pretreatment immune profiling that warrants prospective evaluation.

  • Open Access

    Human ribomes reveal DNA-embedded ribonucleotides as a new type of epigenetic mark

    by Deepali L. Kundnani, Taehwan Yang, Tejasvi Channagiri, Penghao Xu, Yeunsoo Lee, Mo Sun, Francisco Martinez-Figueroa, Supreet Randhawa, Ashlesha Gogate, Youngkyu Jeon, et al.

    Ribonucleoside monophosphates (rNMPs) are abundant in DNA, but their distribution and function in human nuclear genomes remain unknown. Here, we mapped nearly one million rNMPs per genome across diverse human cell types, defining a nuclear “ ribome ” with non-random distribution patterns. rNMPs are enriched in C/G-rich sequences, epigenetically marked regions, and telomeres. Conserved ribonucleotide-enriched zones (REZs) overlap with CpG islands and R-loops. rNMP concentration near transcription start sites (TSSs) correlates positively with gene expression. Wild-type cells display a broader gene-expression range than ribonuclease H2A (RNH2A) knockouts, in which loss of rNMP cleavage causes pronounced retention of embedded rG and strand-biased rC near TSSs, both increasing with gene expression. These findings establish DNA-embedded rNMPs as a novel epigenetic mark that modulates human gene expression.


  • Open Access

    Genome-wide ribonucleotide detection in Archaea

    by Yann Moalic, Maurane Reveil, Deepali L. Kundnani, Sathya Balachander, Taehwan Yang, Alli Gombolay, Farahnaz Ranjbarian, Raphael Brizard, Patrick Durand, Hannu Myllykallio, et al.

    Genome integrity is constantly challenged by the incorporation of ribonucleotides (rNMPs) during DNA synthesis. Covalently linked single and several consecutive rNMPs occur in the genome of a number of organisms. They are mainly introduced by DNA polymerases during DNA replication and repair. In general, cells evolved ribonucleases H (RNases H) specialized in the removal of rNMPs from DNA to avoid any detrimental consequences on genome stability. Here, we describe the involvement of types 1 and/or 2 RNases H in processing embedded rNMPs in the genome of two archaeal species Haloferax volcanii and Thermococcus barophilus . Using combined approaches that include alkaline DNA fragmentation, high-throughput ribose-seq DNA sequencing and nucleotide pool quantification, the distribution, identity, level and sequence context of genomic rNMPs are reported and discussed regards to the intracellular balances of dNTPs and rNTPs. Our results confirm the predominant role of type 2 RNase H in the removal of genomic rNMPs. They also reveal rNMP-base compositions, densities, locations, and variations of surrounding bases at rNMP-embedment for each mutant. The cellular roles of the different RNases H in processing rNMPs in the genome of Archaea are discussed.

  • Open Access

    Distinct features of ribonucleotides within genomic DNA in Aicardi-Goutières syndrome ortholog mutants of Saccharomyces cerevisiae

    by Deepali L. Kundnani, Taehwan Yang, Alli L. Gombolay, Kuntal Mukherjee, Gary Newnam, Chance Meers, Ishika Verma, Kirti Chhatlani, Zeel H. Mehta, Celine Mouawad, et al.


  • Open Access

    rNMPID: a database for riboNucleoside MonoPhosphates in DNA

    by Jingcheng Yang, Mo Sun, Zihan Ran, Taehwan Yang, Deepali L Kundnani, Francesca Storici, Penghao Xu

    Motivation: Ribonucleoside monophosphates (rNMPs) are the most abundant non-standard nucleotides embedded in genomic DNA. If the presence of rNMP in DNA cannot be controlled, it can lead to genome instability. The actual regulatory functions of rNMPs in DNA remain mainly unknown. Considering the association between rNMP embedment and various diseases and cancer, the phenomenon of rNMP embedment in DNA has become a prominent area of research in recent years. Results: We introduce the rNMPID database, which is the first database revealing rNMP-embedment characteristics, strand bias, and preferred incorporation patterns in the genomic DNA of samples from bacterial to human cells of different genetic backgrounds. The rNMPID database uses datasets generated by different rNMP-mapping techniques. It provides the researchers with a solid foundation to explore the features of rNMP embedded in the genomic DNA of multiple sources, and their association with cellular functions, and, in future, disease. It also significantly benefits researchers in the fields of genetics and genomics who aim to integrate their studies with the rNMP-embedment data. Availability and implementation: rNMPID is freely accessible on the web at https://www.rnmpid.org.

  • Open Access

    Distinct features of ribonucleotides within genomic DNA in Aicardi-Goutières syndrome (AGS)-ortholog mutants of Saccharomyces cerevisiae

    by Deepali L. Kundnani, Taehwan Yang, Alli L. Gombolay, Kuntal Mukherjee, Gary Newnam, Chance Meers, Zeel H. Mehta, Celine Mouawad, Francesca Storici

    SUMMARY: Ribonucleoside monophosphates (rNMPs) are abundantly found within genomic DNA of cells. The embedded rNMPs alter DNA properties and impact genome stability. Mutations in ribonuclease (RNase) H2, a key enzyme for rNMP removal, are associated with the Aicardi-Goutières syndrome (AGS), a severe neurological disorder. Here, we engineered two AGS-ortholog mutations in Saccharomyces cerevisiae : rnh201 -G42S and rnh203 -K46W. Using the ribose-seq technique and the Ribose-Map bioinformatics toolkit, we unveiled rNMP abundance, composition, hotspots, and sequence context in these yeast AGS-ortholog mutants. We found higher rNMP incorporation in the nuclear genome of rnh201 -G42S than in wild-type and rnh203- K46W-mutant cells, and an elevated rCMP content in both mutants. Moreover, we uncovered unique rNMP patterns in each mutant, highlighting a differential activity of the AGS mutants towards rNMPs embedded on the leading or on the lagging strand of DNA replication. This study guides future research on rNMP characteristics in human genomic samples carrying AGS mutations.

  • Open Access

    Gene Co-Expression Analysis of Human RNASEH2A Reveals Functional Networks Associated with DNA Replication, DNA Damage Response, and Cell Cycle Regulation

    by Stefania Marsili, Ailone Tichon, Deepali Kundnani, Francesca Storici

    Ribonuclease (RNase) H2 is a key enzyme for the removal of RNA found in DNA-RNA hybrids, playing a fundamental role in biological processes such as DNA replication, telomere maintenance, and DNA damage repair. RNase H2 is a trimer composed of three subunits, RNASEH2A being the catalytic subunit. RNASEH2A expression levels have been shown to be upregulated in transformed and cancer cells. In this study, we used a bioinformatics approach to identify RNASEH2A co-expressed genes in different human tissues to underscore biological processes associated with RNASEH2A expression. Our analysis shows functional networks for RNASEH2A involvement such as DNA replication and DNA damage response and a novel putative functional network of cell cycle regulation. Further bioinformatics investigation showed increased gene expression in different types of actively cycling cells and tissues, particularly in several cancers, supporting a biological role for RNASEH2A but not for the other two subunits of RNase H2 in cell proliferation. Mass spectrometry analysis of RNASEH2A-bound proteins identified players functioning in cell cycle regulation. Additional bioinformatic analysis showed that RNASEH2A correlates with cancer progression and cell cycle related genes in Cancer Cell Line Encyclopedia (CCLE) and The Cancer Genome Atlas (TCGA) Pan Cancer datasets and supported our mass spectrometry findings.


  • Open Access

    CES2 Expression in Pancreatic Adenocarcinoma Is Predictive of Response to Irinotecan and Is Associated With Type 2 Diabetes

    by Michela Capello, Johannes F. Fahrmann, Mayrim V. Rios Perez, Jody V. Vykoukal, Ehsan Irajizad, Satyendra C. Tripathi, David Roife, Leonidas E. Bantis, Ya’an Kang, Deepali L. Kundnani, et al.

    The combination chemotherapy of fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) has provided clinically meaningful improvement for pancreatic ductal adenocarcinoma (PDAC). We previously uncovered a role for the serine hydrolase carboxylesterase 2 (CES2) in mediating intratumoral activation of the prodrug irinotecan, a constituent of FOLFIRINOX. We aimed to further test the predictive value of CES2 for response to irinotecan using patient-derived xenograft (PDX) models and to elucidate the determinants of CES2 expression and response to FOLFIRINOX treatment among patients with PDAC. PDXs were engrafted subcutaneously into nude mice and treated for 4 weeks with either saline control or irinotecan. CES2 and hepatocyte nuclear factor 4 alpha (HNF4A) expression in PDAC tissues was evaluated by immunohistochemical and Western blot analysis. Kaplan-Meier and Cox regression analyses were applied to assess the association between overall survival and hemoglobin A1C (HbA1C) levels in patients who underwent neoadjuvant FOLFIRINOX treatment. High CES2 activity in PDAC PDXs was associated with increased sensitivity to irinotecan. Integrated gene expression, proteomic analyses, and in vitro genetic experiments revealed that nuclear receptor HNF4A, which is upregulated in diabetes, is the upstream transcriptional regulator of CES2 expression. Elevated CES2 protein expression in PDAC tissues was positively associated with a history of type 2 diabetes (odds ratio, 4.84; P = .02). High HbA1C levels were associated with longer overall survival in patients who received neoadjuvant FOLFIRINOX treatment (P = .04). To our knowledge, we provide, for the first time, evidence that CES2 expression is associated with a history of type 2 diabetes in PDAC and that elevated HbA1C, by predicting tumor CES2 expression, may represent a novel marker for stratifying patients most likely to respond to FOLFIRINOX therapy.


  • Open Access

    NFATc Acts as a Non-Canonical Phenotypic Stability Factor for a Hybrid Epithelial/Mesenchymal Phenotype

    by Ayalur Raghu Subbalakshmi, Deepali Kundnani, Kuheli Biswas, Anandamohan Ghosh, Samir M. Hanash, Satyendra C. Tripathi, Mohit Kumar Jolly

    Metastasis remains the cause of over 90% of cancer-related deaths. Cells undergoing metastasis use phenotypic plasticity to adapt to their changing environmental conditions and avoid therapy and immune response. Reversible transitions between epithelial and mesenchymal phenotypes – epithelial–mesenchymal transition (EMT) and its reverse mesenchymal–epithelial transition (MET) – form a key axis of phenotypic plasticity during metastasis and therapy resistance. Recent studies have shown that the cells undergoing EMT/MET can attain one or more hybrid epithelial/mesenchymal (E/M) phenotypes, the process of which is termed as partial EMT/MET. Cells in hybrid E/M phenotype(s) can be more aggressive than those in either epithelial or mesenchymal state. Thus, it is crucial to identify the factors and regulatory networks enabling such hybrid E/M phenotypes. Here, employing an integrated computational-experimental approach, we show that the transcription factor nuclear factor of activated T-cell (NFATc) can inhibit the process of complete EMT, thus stabilizing the hybrid E/M phenotype. It increases the range of parameters enabling the existence of a hybrid E/M phenotype, thus behaving as a phenotypic stability factor (PSF). However, unlike previously identified PSFs, it does not increase the mean residence time of the cells in hybrid E/M phenotypes, as shown by stochastic simulations; rather it enables the co-existence of epithelial, mesenchymal and hybrid E/M phenotypes and transitions among them. Clinical data suggests the effect of NFATc on patient survival in a tissue-specific or context-dependent manner. Together, our results indicate that NFATc behaves as a non-canonical PSF for a hybrid E/M phenotype.